Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Semaglutide as a potential therapeutic adjunct for reducing flare-ups in Sjögren's syndrome: A case report.

Jung J, Zazay I, Kalia P, Shaghaghi N, Ross N, Homan B

SAGE open medical case reports31 Aug 2025

PMID40900762 (opens in a new tab)PMCIDPMC12399809 (opens in a new tab)DOI10.1177/2050313x251372813 (opens in a new tab)PepBankPUB-40900762
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Sjögren's syndrome is a chronic autoimmune disorder with limited therapeutic options. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used for diabetes and obesity, have emerging evidence of anti-inflammatory and immunomodulatory effects. We present a case of a 37-year-old woman with primary Sjögren's syndrome and comorbid Hashimoto's thyroiditis and seronegative rheumatoid arthritis, who experienced frequent debilitating flares affecting her quality of life. After starting semaglutide for weight management and losing over 100 lbs, the patient reported a dramatic reduction in flare frequency and duration, with episodes decreasing from multi-week flares to approximately a single day. This case suggests that semaglutide may offer dual benefits in Sjögren's syndrome by combining substantial weight reduction with possible direct immunomodulatory effects. Further research is warranted to explore GLP-1 agonists as adjunctive therapy in the management of autoimmune diseases.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 37-year-old woman with primary Sjogren's syndrome, flare frequency and duration decreased after starting semaglutide, from multi-week flares to about a single day.

    In plain wordsA 37-year-old woman with Sjogren's syndrome had much shorter and fewer flares after starting semaglutide; one case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    DecreaseFlare frequency and duration
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After starting semaglutide for weight management and losing over 100 lbs, the patient reported a dramatic reduction in flare frequency and duration, with episodes decreasing from multi-week flares to approximately a single day.
    1 context sentence
    Summary · context
    We present a case of a 37-year-old woman with primary Sjögren's syndrome and comorbid Hashimoto's thyroiditis and seronegative rheumatoid arthritis, who experienced frequent debilitating flares affecting her quality of life.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 37-year-old woman with primary Sjogren's syndrome, semaglutide for weight management was followed by weight loss of over 100 lbs.

    In plain wordsA 37-year-old woman lost over 100 lbs after starting semaglutide for weight management; this is one case.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After starting semaglutide for weight management and losing over 100 lbs, the patient reported a dramatic reduction in flare frequency and duration, with episodes decreasing from multi-week flares to approximately a single day.
    1 context sentence
    Summary · context
    We present a case of a 37-year-old woman with primary Sjögren's syndrome and comorbid Hashimoto's thyroiditis and seronegative rheumatoid arthritis, who experienced frequent debilitating flares affecting her quality of life.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.